Study of newer antibodies for B-cell lymphoma in Italy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study watches how newer monoclonal antibodies (targeted therapies) work for people with B-cell non-Hodgkin lymphoma in real-world Italian clinics. It helps doctors learn more about how these treatments affect patients in everyday care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called B-cell non-Hodgkin lymphoma.
- Your doctor has decided you need treatment for your lymphoma.
- Your treatment plan includes a newer monoclonal antibody (a targeted therapy) that has been approved in Europe since 2020.
- You are not taking part in another experimental treatment trial.
- You are 18 years or older.
- You can give your permission to be in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well newer antibody treatments work for B-cell non-Hodgkin lymphoma. It uses blood and tissue samples to learn more about the treatment, which may help guide better care.
This study is for adults newly diagnosed with lymphoma in the last 3 months, including those who may have started treatment. It aims to collect information on patients in Italy.
This study observes patients with certain lymphomas who are already eligible for standard CAR-T cell therapy in Italy. It aims to gather real-world information about how these treatments work.
This is a study that looks back and forward at people diagnosed with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or a related early condition called MBL. It aims to improve how these conditions are recognized and managed over time in Italy.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
This trial tests a new drug called JNJ-95566692 for people with a type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if the drug can help when no other standard options are available.
Hear when a new Non-Hodgkin Lymphoma, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.